Open main menu

Biolecture.org β

Changes

Rosetta Genomics

206 bytes added, 12:35, 16 January 2009
no edit summary
<font size="4"><strong>Rosetta Genomics Overview<br /></strong></font> <br />
<br />
Rosetta Genomics is a developer of microRNA-based diagnostic tests and therapeutic tools.&nbsp;<br />
MicroRNAs (miRNAs) are a recently discovered group of short (21&ndash;23 nucleotides in length), non-coding genes which regulate the expression of other genes.&nbsp;<br />
MicroRNAs have also been shown to have varying expression levels across various pathological conditions, and offer a new class of highly sensitive and tissue specific biomarkers. MicroRNA-based diagnostics may offer physicians and patients an objective tool to accurately identify cancer, predict outcomes and help guide treatment. <br />
<br />
<strong><font size="3">Rosetta Genomics Platform Technologies</font></strong> <br />
<br />
Backed by a strong IP portfolio, Rosetta Genomics is a leading developer of microRNA-based diagnostic tests and therapeutic tools. MicroRNAs (miRNAs) are a recently discovered group of short (21&ndashrsquo;23 nucleotides in length)scientists have developed proprietary platform technologies for the identification, extraction, non-coding genes which regulate the expression of other genes. MicroRNAs have also been shown to have varying expression levels across various pathological conditionsquantification, and offer analysis of microRNAs from a new class wide range of highly sensitive and tissue specific biomarkerssample types. MicroRNA-based diagnostics may offer physicians These technologies enable the identification and patients an objective tool to accurately identify advancement of multiple diagnostic projects addressing critical unmet needs in cancer, predict outcomes women&rsquo;s health and help guide treatmentother indications. more <br />
<br />
Platform Technologies <br font size="3"><strong>Rosetta Genomics Development Engine</strong><br /font>Backed by a strong IP portfolio, Rosetta Genomics&rsquo; scientists have developed proprietary platform technologies for the identification, extraction, quantification, and analysis of microRNAs from a wide range of sample types. These technologies enable the identification and advancement of multiple diagnostic projects addressing critical unmet needs in cancer, women&rsquo;s health and other indications. more <br />
<br />
Development Engine Based on our strong IP position which provides us access to hundreds of potential microRNAs biomarkers, our proprietary technologies, and our extensive network of collaborations, Rosetta Genomics has put in place a powerful development engine which can rapidly advance a wide range of microRNA-based tests. more&nbsp;<br />
<br />
Based on our strong IP position which provides us access to hundreds of potential microRNAs biomarkers, our proprietary technologies, and our extensive network of collaborations, Rosetta Genomics has put in place a powerful development engine which can rapidly advance a wide range of microRNA-based tests. more <br />
<br />
<font size="3"><strong>Rosetta Genomics Advancing Cutting Edge Molecular Diagnostics </strong></font> <br />
<br />
Rosetta Genomics&rsquo; proprietary technologies enable the development of a wide range of diagnostic tests for cancer and women&rsquo;s health indications. Rosetta genomics believes that utilizing microRNAs as biomarkers in the development of next generation molecular diagnostics, presents several advantages over other currently used methods: <br />
3.141.35.27
0
edits
Retrieved from "https://Biolecture.org/Special:MobileDiff/2357"